RetinalGenix Technologies Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing near-zero cash, a nine-month net loss of $1,330,911, and a stockholders' deficit of $2,028,197.
Key Highlights
- Cash at quarter-end: The company reported cash of $5 as of September 30, 2026, down from $14,774 at December 31, 2025.
- No revenue: The company reported $0 in revenues for both the three months and nine months ended September 30, 2026.
- Nine-month net loss: Net loss for the nine months ended September 30, 2026 was $1,330,911, compared to $1,805,468 for the same period in 2025.
- Accumulated deficit: The accumulated deficit reached $19,189,528 as of September 30, 2026, up from $17,858,617 at December 31, 2025.
- Sanovas debt retirement: During Q3 2026, the company retired amounts due to Sanovas Ophthalmology LLC through the issuance of 442,670 shares of common stock, valued at $996,007 according to the filing.
- Shares outstanding: Common shares outstanding as of November 16, 2026 were 19,290,520, with a par value of $0.0001 per share.
- Total assets: Total assets were $4,346 as of September 30, 2026, against total liabilities of $2,032,543.
RetinalGenix Financial Position and Operating Activity for the Nine Months Ended September 30, 2026
According to the filing, RetinalGenix Technologies Inc. generated no revenues during the three or nine months ended September 30, 2026. Total operating expenses for the nine-month period were $1,324,171, composed of general and administrative expenses of $749,810, research and development costs of $295,043, and stock-based compensation of $279,318. For the comparable nine-month period in 2025, total operating expenses were $1,802,531, with stock-based compensation alone accounting for $759,348 of that total.
The company disclosed that cash at the end of the nine-month period stood at $5, with net cash used in operating activities of $328,368. Financing activities provided $313,599, including $205,000 from the sale of common stock, $125,000 from collection of a stock subscription receivable, and $50,000 from proceeds on a new note payable. Accounts payable and accrued liabilities increased to $1,307,879 at September 30, 2026, from $1,084,763 at December 31, 2025. The filing also shows that amounts due to Sanovas declined from $674,842 to $165,375, reflecting the Q3 share-based settlement of $996,007.
The stockholders' deficit narrowed to $2,028,197 as of September 30, 2026, compared to $2,302,611 at December 31, 2025, primarily due to the retirement of the Sanovas obligation via equity issuance. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing does not name an exchange or trading symbol in its registered securities table, indicating no securities are registered under Section 12(b) of the Act, as the cover page states "None" under that heading.
What Was Disclosed
RetinalGenix Technologies Inc. disclosed its unaudited condensed consolidated financial statements for the nine months ended September 30, 2026, showing $5 in cash, no revenues, a nine-month net loss of $1,330,911, and a total stockholders' deficit of $2,028,197.




Please wait processing your request...